VeraBIND Tau

The VeraBIND™ Tau assay is a novel blood test of tau pathology. Unlike traditional methods that focus on quantifying biomarker levels, the VeraBIND Tau identifies the presence of active tau pathology, which may provide a more direct measure of tau-related disease. A preliminary study of the assay conducted by Veravas and Saint Luc University Hospital, Institute of Neuroscience, UCLouvain have demonstrated the assay’s ability to correctly measure tau pathology in a wide range of patients, including those who are cognitively unimpaired, those with Mild Cognitive Impairment (MCI), and diagnosed with Alzheimer’s disease (AD) dementia.

VeraBIND Tau is being developed jointly with Veravas, Inc. and Phanes Biotech, Inc.

Unmet Need

There is an urgent unmet clinical need for a noninvasive, inexpensive and accessible testing solution that can predict cognitive decline and screen patients for tau pathology.1 With the advancement of therapies focused on Alzheimer’s disease (AD), a test is needed to identify cognitively unimpaired individuals at risk of developing AD, which may be indicative of future cognitive impairment.

Join the VeraBIND Tau assay early access program

Get early access

Intended Use

The VeraBIND™ Tau assay measures the pathological activity of hyperphosphorylated tau in blood samples of cognitively normal individuals or individuals experiencing cognitive impairment. Results can be used to aid in the diagnosis of Alzheimer's disease.

Limitations of Use

The performance of the VeraBIND Tau assay has not been established for: 

Staging disease

Monitoring responses to therapies 

Additional Reading

For those looking to learn more about testing and managing AD, we recommend the following articles.

  1. The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia 2

    Why read: Provides a practical guide for primary care physicians on early detection, differential diagnosis, and effective management strategies for AD to improve patient outcomes in a generalist setting.


  2. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021 3

    Why read: Discusses the importance of early AD detection and provides practical guidance for clinicians on diagnosis steps, including recognizing early symptoms, utilizing biomarker and imaging assessments, and implementing a coordinated care approach to improve outcomes for patients in the early stages of the disease.


  3. Basic Resources on Alzheimer's disease for the Primary Healthcare Professional 4

    Why Read: This is a library of content prepared by the Alzheimer's Association offering a curated list of educational materials, diagnostic tools, management guides, and additional resources specifically designed to aid primary care physicians in assessing, diagnosing, and managing Alzheimer's disease in community settings.

VeraBIND Tau is being developed jointly with Veravas, Inc. and Phanes Biotech, Inc.

Read press release

  1. Li TR, Yang Q, Hu X, Han Y. Biomarkers and Tools for Predicting Alzheimer's Disease in the Preclinical Stage. Curr Neuropharmacol. 2022;20(4):713-737. doi:10.2174/1570159X19666210524153901 https://pmc.ncbi.nlm.nih.gov/articles/PMC9878962/

  2. Reiss AB, de Levante Raphael D, Chin NA, Sinha V. The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia. AIMS Public Health. 2022;9(4):661-689. Published 2022 Sep 27. doi:10.3934/publichealth.2022047 https://pmc.ncbi.nlm.nih.gov/articles/PMC9807411/

  3. Porsteinsson, A.P., Isaacson, R.S., Knox, S. et al. Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021. J Prev Alzheimers Dis 8, 371–386 (2021). https://doi.org/10.14283/jpad.2021.23 | https://pubmed.ncbi.nlm.nih.gov/34101796/

  4. Alzheimer’s Association. 2024 Alzheimer’s Disease Facts and Figures. Alzheimers Dement 2024;20(5). https://www.alz.org/alzheimers-dementia/facts-figures